Improving Cancer Screening with AI

A closer look in research about algorithms that can be used in detecting Colorectal cancer, Hepatocellular carcinoma and Prostate cancer.
Systems based on AI have been incorporated at various stages in the breast cancer screening process. Based on the research some algorithm could increase breast cancer detection by 12-27%. (1)
In a research, studying patients who undergo lung cancer screening using low dose CT, AI has shown promise for the automatic detection of lung nodules likely to represent malignancy. (2)

Bibliography

1. Dembrower, K., Wåhlin, E., Liu, Y., Salim, M., Smith, K., Lindholm, P., Eklund, M., & Strand, F. (2020). Effect of artificial intelligence-based triaging of breast cancer screening mammograms on cancer detection and radiologist workload: a retrospective simulation study. The Lancet. Digital Health, 2(9), e468–e474. https://doi.org/10.1016/S2589-7500(20)30185-0

2. Chamberlin, J., Kocher, M. R., Waltz, J., Snoddy, M., Stringer, N. F. C., Stephenson, J., Sahbaee, P., Sharma, P., Rapaka, S., Schoepf, U. J., Abadia, A. F., Sperl, J., Hoelzer, P., Mercer, M., Somayaji, N., Aquino, G., & Burt, J. R. (2021). Automated detection of lung nodules and coronary artery calcium using artificial intelligence on low-dose CT scans for lung cancer screening: accuracy and prognostic value. BMC Medicine, 19(1), 55. https://doi.org/10.1186/s12916-021-01928-3

The descriptions, claims and visuals for all non-Bayer owned applications originate and are obtained from the application providers, or excerpted from publicly available information. Bayer is providing this content for your information, but does not own and control such content.

BAYER, the Bayer Cross and Calantic are trademarks owned by Bayer and/or registered in the U.S. and/or other countries. Other trademarks and company names mentioned herein are properties of their respective owners.

This is intended to provide information for healthcare professionals and other relevant decision makers in the US, European Union, United Kingdom and Switzerland. Not all offerings are available in all markets. For availability specific to your country please contact your local Bayer representative. These materials are exclusively for professional use.

The product Calantic Viewer has CE marking (CE2797). Complies with medical device legislation. Consult the operating instructions of a product for its intended use, characteristics and performance, contraindications, name of the manufacturer or its authorized representative and other essential information. The operating instructions of the product Calantic Viewer can be found on https://www.radiology.bayer.com/manuals

You are encouraged to report adverse events; reporting information can be found on https://www.bayer.com/en/pharma/report-side-effect

Any individuals depicted in this website are actors and not actual health care providers or patients. All patient data is fictitious. Images are an artistic representation for illustrative purposes only.

PP-CALA-ALL-0662-1 October 2023

Improving Cancer Screening: How AI Empowers Radiologists